Modulators of CaV1.3 Ca2+ regulation
CaV1.3 Ca2 调节的调节剂
基本信息
- 批准号:8542901
- 负责人:
- 金额:$ 3.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-10 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffectAgonistAtrial FibrillationAttenuatedAwarenessBasic ScienceBehaviorBindingBiological AssayBlood VesselsBrainBreathingCalcium ChannelCalmodulinCardiacCardiovascular systemCell NucleusCellsChemicalsCircadian RhythmsCoupledDihydropyridinesDoctor of PhilosophyDoseElectrophysiology (science)ElementsFeedbackFluorescence Resonance Energy TransferFunctional disorderGoalsHair CellsHandHeartIndividualKnowledgeL-Type Calcium ChannelsLaboratoriesLeadLibrariesLifeLocomotionMediatingMicroscopeMolecularMotorMuscle ContractionNeurodegenerative DisordersOutcomeParkinson DiseasePathologyPeriodicityPharmacologic SubstancePhysiologicalPhysiologyProtocols documentationPublished CommentReaderRecombinantsRegulationRoleSignal TransductionSkeletal MuscleSpeedSubstantia nigra structureSystemTestingTherapeuticToxic effectUrsidae Familybasecounterscreendihydropyridinefluorophoreimprovedinhibitor/antagonistneurotransmitter releasenovelnovel strategiespatch clamppositive moodresponseribbon synapsesmall moleculestable cell linetoolvoltage
项目摘要
DESCRIPTION (provided by applicant): CaV1.3 channels are low-threshold, dihydropyridine-sensitive L-type Ca2+ channels which mediate low-voltage signaling and rhythmicity throughout the body. They are essential for neurotransmitter release at ribbon synapses such as found in cochlear hair cells; they mediate pacemaking in the heart; and they modulate oscillatory behavior throughout the brain, such as the repetitive bursting in supra-chiasmatic (circadian pacemaking circuitry) and substantia nigra (locus of primary damage in Parkinson's) nuclei. As such, overactivity of these channels may predispose for Ca2+ overload precipitating Parkinson's, and downward modulation of these channels may enhance positive mood and affect. Clearly, small-molecule compounds that selectively inhibit or enhance CaV1.3 channels, rather than the other CaV1 L-type channels would be of enormous utility for basic studies of CaV1.3 roles, and for potentially amerliorating a number of CaV1.3-related pathologies. However, though excellent L-type channels antagonists and agonists have been discovered, none can truly select among the L-type channel subtypes. Here, in the search for selective modulators, we will exploit a unique molecular interaction between ICDI and IQ domains of CaV1.3 channels, where this interaction modulates the strength Ca2+ feedback inhibition (CDI) of these channels. This promising screen will be prosecuted according to three specific aims. 1) To perform a primary screen for small molecules that disrupt or enhance a functionally critical interaction between IQ and ICDI domains of CaV1.3 channels, using the MLSMR library of 350,000-500,00 compounds. 2) To confirm and identify candidate hits from Aim 1 using a microscope-based FRET analysis of single living cells. 3) To test candidate compounds for modulation of CaV1.3 Ca2+ regulation, using patch-clamp electrophysiology. Overall, this project promises lead candidates for selective modulators of CaV1.3 versus other CaV1 L-type calcium channels.
描述(由申请人提供):CAV1.3通道是低阈值,二氢吡啶敏感的L型Ca2+通道,可介导整个身体的低压信号传导和节奏性。它们对于在耳蜗细胞中发现的色带突触中的神经递质释放至关重要。他们介导心脏中的起搏。它们调节整个大脑中的振荡行为,例如上chiasmmantic(昼夜节律起搏回路)和底底nigra(帕金森氏症中主要损害的基因座)的重复爆发。因此,这些通道的过度活动性可能会使Ca2+过载帕金森氏症的过载易感性,并且对这些通道的下降调节可能会增强积极的情绪和影响。显然,对于有选择地抑制或增强CAV1.3通道的小分子化合物,而不是其他CAV1 L型通道对于Cav1.3角色的基本研究以及可能会进行一些社会化的CAV1.3相关病理学,将具有巨大的实用性。但是,尽管已经发现了出色的L型拮抗剂和激动剂,但没有人能真正在L型通道亚型中进行选择。在这里,在寻找选择性调节器时,我们将利用CAV1.3通道的ICDI和IQ域之间的独特分子相互作用,其中这种相互作用调节了这些通道的强度Ca2+反馈抑制(CDI)。这个有希望的屏幕将根据三个特定目标起诉。 1)使用350,000-500,00化合物的MLSMR库进行破坏或增强CAV1.3通道智商和ICDI域之间功能关键相互作用的小分子。 2)使用基于显微镜的单个活细胞分析AIM 1的候选命中。 3)使用Patch-Clamp电生理学测试候选化合物,以调节CAV1.3 Ca2+调节。总体而言,该项目有望为CAV1.3选择性调节剂与其他CAV1 L型钙通道的选择性调节剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID T YUE其他文献
DAVID T YUE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID T YUE', 18)}}的其他基金
Chemical biological dissection of Ca2+ entry through Ca2+ channels
Ca2+通过Ca2+通道进入的化学生物学解剖
- 批准号:
8609908 - 财政年份:2013
- 资助金额:
$ 3.93万 - 项目类别:
相似国自然基金
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:82101697
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境激素壬基酚对变应性鼻炎的影响及其对GPER特异性激动剂G-1在变应性鼻炎治疗作用中的干扰机制研究
- 批准号:82000963
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
促生长激素释放激素激动剂抑制平滑肌细胞转分化对动脉粥样硬化的影响及机制研究
- 批准号:81900389
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
五羟色胺2C受体激动剂对2型糖尿病小鼠β细胞功能的影响及机制研究
- 批准号:81803644
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Multifunctional Nanoparticle Platform to Prevent Alcohol-Associated HCC Development
多功能纳米颗粒平台可预防酒精相关的 HCC 发展
- 批准号:
10736984 - 财政年份:2023
- 资助金额:
$ 3.93万 - 项目类别:
Effect of maternal obesity on breast cancer among offspring: role of the gut microbiota
母亲肥胖对后代乳腺癌的影响:肠道微生物群的作用
- 批准号:
10734892 - 财政年份:2023
- 资助金额:
$ 3.93万 - 项目类别:
HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities
HER1-3 和死亡受体蛋白折叠作为治疗漏洞
- 批准号:
10721930 - 财政年份:2023
- 资助金额:
$ 3.93万 - 项目类别:
Mechanisms of Hypoxia-Mediated Disturbances in Cerebral Maturation in a Fetal Ovine Model of Maternal Sleep Apnea
母体睡眠呼吸暂停胎羊模型中缺氧介导的大脑成熟障碍的机制
- 批准号:
10608612 - 财政年份:2023
- 资助金额:
$ 3.93万 - 项目类别:
An exploratory randomized controlled trial of the effects of oral semaglutide on alcohol craving and consumption
口服索马鲁肽对酒精渴望和消费影响的探索性随机对照试验
- 批准号:
10747743 - 财政年份:2023
- 资助金额:
$ 3.93万 - 项目类别: